Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Tarazi FI, Schetz JA (eds). Neurological and psychiatric disorders. United States. 2005: ISBN 978-1-59259-856-4;
https://doi.org/10.1385/1592598560
.
2. Potturi PK, Sudhakar Y. Formulation and in vitro/in vivo evaluation of controlled release Entacapone trilayer matrix tablets by geomatrix. Int J Drug Deliv. 2015;7:155–66.
3. Paci C, Sanguigni S, Carboni T, Gobbato R, Curatola L. The use of entacapone in patients with advanced Parkinson’s disease: 2 years’ experience. Neurol Sci. 2003;24(3):197–8.
4. Baek JS, Choo CC, Qian C, Tan NS, Shen Z, Loo SCJ. Multi-drug-loaded microcapsules with controlled release for management of Parkinson’s disease. Small. 2016;12:3712–22.
5. Grünig D, Felser A, Bouitbir J, Krähenbühl S. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells. Toxicol Vitr. 2017;42:337–47.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献